ASTS
AST SpaceMobile, Inc.
ASTS offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
BMI
Badger Meter, Inc.
BMI has the edge over ASTS overall, supported by lower modeled downside and stronger valuation.
ASTS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
ASTS's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
BMI Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Strong |
BMI's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
ASTS PE Valuation
ASTS has no meaningful PE right now: it lost money over the past year.
BMI PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 32x | $154 | — |
| Current | 35x | $154 | — |
| Cheap | 37x | $160 | +4.3% |
| Fair | 49x | $212 | +38% |
| Expensive | 55x | $238 | +55% |
Historical ranges are pointers, not guarantees.
BMI's PE is in its cheap range at 35x. If earnings grow as analysts expect, today's price would be 32x next year's earnings.
ASTS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect ASTS's losses to grow, with revenue growing. However, they disagree widely on these estimates.
BMI Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Stable | |
| Stable | |
| Limited | |
| Moderate |
Analysts expect BMI's earnings to grow, with its revenue and profitability holding steady.
ASTS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.15 | -$0.91 |
| Q2 2026 | -$2.16 | -$0.27 |
| Q1 2026 | -$1.80 | +$0.19 |
| Q4 2025 | -$1.34 | +$0.61 |
| Q3 2025 | -$1.24 | +$0.88 |
| Q2 2025 | -$1.89 | -$0.64 |
| Q1 2025 | -$1.99 | -$1.01 |
| Q4 2022 | -$0.58 | -$0.21 |
ASTS is still losing money, but far less than before: $2.15 per share over the past year, against $5.76 at its worst in mid-2021.
BMI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.87 | +12% |
| Q3 2026 | $4.33 | -7.9% |
| Q2 2026 | $4.28 | -6.8% |
| Q1 2026 | $4.43 | -2.4% |
| Q4 2025 | $4.80 | +13% |
| Q3 2025 | $4.70 | +17% |
| Q2 2025 | $4.59 | +20% |
| Q1 2025 | $4.54 | +31% |
| Q4 2024 | $4.23 | +35% |
BMI has the edge over ASTS on earnings quality, reporting a profit while its opponent remains loss making.
ASTS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $42.3M | +187% |
| Q2 2026 | $31.5M | +2627% |
| Q1 2026 | $14.7M | +1952% |
| Q4 2025 | $54.3M | +2731% |
| Q3 2025 | $14.7M | +1240% |
| Q2 2025 | $1.2M | +28% |
| Q1 2025 | $718K | +44% |
| Q3 2022 | $4.2M | +70% |
ASTS has the edge over BMI on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -415% | +694 points |
| Q2 2026 | -948% | +10744 points |
| Q1 2026 | -1686% | +7083 points |
| Q4 2025 | -175% | +2446 points |
| Q3 2025 | -1109% | +4850 points |
| Q2 2025 | -11692% | -4693 points |
| Q1 2025 | -8769% | +2331 points |
| Q4 2024 | -2621% | N/A |
ASTS's operating margin was −415% last quarter, up 694 points from the same quarter a year ago.
BMI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $235.9M | +0.1% |
| Q2 2026 | $222.3M | -6.6% |
| Q1 2026 | $202.3M | -9% |
| Q4 2025 | $220.7M | +7.6% |
| Q3 2025 | $235.7M | +13% |
| Q2 2025 | $238.1M | +9.9% |
| Q1 2025 | $222.2M | +13% |
| Q4 2024 | $205.2M | +12% |
BMI's revenue grew through 2024 and has held roughly level since: $236M last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 20% | +0.7 points |
| Q2 2026 | 18% | -1.1 points |
| Q1 2026 | 17% | -4.8 points |
| Q4 2025 | 20% | +0.4 points |
| Q3 2025 | 20% | +0.1 points |
| Q2 2025 | 19% | -0.3 points |
| Q1 2025 | 22% | +3.6 points |
| Q4 2024 | 19% | +1.5 points |
BMI has the edge over ASTS on profitability, with a higher operating margin.
ASTS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$464.2M | -$161.4M |
| Q2 2026 | -$694.8M | -$341.1M |
| Q1 2026 | -$309.7M | -$160.7M |
| Q4 2025 | -$330.7M | -$220.3M |
| Q3 2025 | -$302.9M | -$239.1M |
| Q2 2025 | -$353.6M | -$315.3M |
| Q1 2025 | -$149M | -$61.3M |
| Q4 2024 | -$110.5M | -$63.2M |
ASTS has burned cash in almost every quarter: −$1.8B over the past year, against −$916M the year before.
BMI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $40.3M | -16% |
| Q2 2026 | $21.9M | -46% |
| Q1 2026 | $29.5M | -2% |
| Q4 2025 | $50.8M | +7.1% |
| Q3 2025 | $48.2M | +15% |
| Q2 2025 | $40.6M | +19% |
| Q1 2025 | $30.1M | +60% |
| Q4 2024 | $47.4M | +32% |
BMI has the edge over ASTS on cash generation, producing positive trailing cash flow while its opponent burns cash.
ASTS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +1.1M shares |
| 1 year | +10% | +27.3M shares |
| 3 years | +235% | +211M shares |
| 5 years | +480% | +248M shares |
| Available history | +944% | +271M shares |
ASTS has 300M diluted shares, up 10% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
BMI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.9% | -271K shares |
| 1 year | -2.4% | -712K shares |
| 3 years | -1.9% | -550K shares |
| 5 years | -1.3% | -395K shares |
BMI has the edge over ASTS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $55.5M |
| Q2 2026 | $25.3M |
| Q1 2026 | $38.2M |
| Q4 2022 | — |
| Q3 2022 | — |
| Q4 2021 | — |
| Q3 2021 | — |
| Q4 2020 | $182,000 |
ASTS Net Leverage
ASTS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
BMI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.4x | Net Cash |
| Q2 2026 | -0.6x | Net Cash |
| Q1 2026 | -1.1x | Net Cash |
| Q4 2025 | -1.2x | Net Cash |
| Q3 2025 | -1.1x | Net Cash |
| Q2 2025 | -0.9x | Net Cash |
| Q1 2025 | -0.7x | Net Cash |
| Q4 2024 | -1.8x | Net Cash |
BMI has more cash than debt.
ASTS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.1 | Neutral |
| Stochastic | 11.9 | Oversold |
ASTS's weekly RSI is 34 (neutral) and its Stochastic is 12 (oversold).
BMI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.6 | Neutral |
| Stochastic | 74.5 | Neutral |
BMI's weekly RSI is 58 (neutral) and its Stochastic is 75 (neutral).
ASTS PE vs Technology Sector
ASTS has no meaningful PE right now: it lost money over the past year.
BMI PE vs Technology Sector
| Metric | BMI | Sector median | Relative |
|---|---|---|---|
| PE | 35x | 28x | 27% above |
| PE % | 14 | 35 | 21 pts below |
BMI is trading at 35x earnings, a 27% premium to the Technology sector's median of 28x.
ASTS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $44.9 | 23% below |
| 20 week MA | $57.1 | 40% below |
| 50 week MA | $75.5 | 54% below |
| 100 week MA | $57.8 | 40% below |
| 200 week MA | $33.6 | 2.8% above |
ASTS has fallen below most of its moving averages, though it's still 2.8% above its 200-week average.
BMI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $140.8 | 9.1% above |
| 20 week MA | $137.7 | 12% above |
| 50 week MA | $144.3 | 6.4% above |
| 100 week MA | $174.9 | 12% below |
| 200 week MA | $169.6 | 9.5% below |
BMI has the edge over ASTS on trend strength, trading above more of its moving averages.
ASTS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.87 | $13.4 | +36% |
| 2021 | $13.4 | $8.71 | -35% |
| 2022 | $8.71 | $3.97 | -54% |
| 2023 | $3.97 | $6.03 | +52% |
| 2024 | $6.03 | $22.9 | +280% |
| 2025 | $22.9 | $72.0 | +214% |
| 2026 YTD | $72.0 | $34.5 | -52% |
ASTS's yearly returns have swung widely, from +280% in 2024 to −54% in 2022. It's down 52% so far in 2026.
BMI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $66.1 | $93.7 | +42% |
| 2021 | $93.7 | $105.2 | +12% |
| 2022 | $105.2 | $109.6 | +4.2% |
| 2023 | $109.6 | $154.4 | +41% |
| 2024 | $154.4 | $215.5 | +40% |
| 2025 | $215.5 | $180.8 | -16% |
| 2026 YTD | $180.8 | $153.6 | -15% |
BMI has the edge over ASTS on returns for 2026, with the stronger performance.